# The Rise of Functional Cannabis: Beyond Getting High | MEXC News > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/the-rise-of-functional-cannabis-beyond-getting-high-mexc-news/ > **Published:** 2026-05-21T17:48:18-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:54:30-04:00 > **Clinical Summary:** Functional cannabis and CBD offer therapeutic endocannabinoid engagement without intoxication. Clinical evidence, dosing, and patient selection. --- ✦ New CED Clinical Relevance #68 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CBDAnxietyMental HealthResearchSafetyIndustryHemp Clinical Summary # Clinical Summary The emergence of functional cannabis products, particularly those emphasizing cannabidiol (CBD) and other [non-intoxicating cannabinoids](https://cedclinic.com/cbg-clinical-trial-anxiety-stress-relief/), represents a shift toward therapeutically-targeted formulations that engage the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) while minimizing psychoactive effects and [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/). These products address a significant clinical gap for patients seeking symptom relief from conditions such as anxiety, inflammation, and pain without the functional limitations associated with THC-dominant preparations. The development of CBD-rich and balanced cannabinoid formulations may improve patient adherence and real-world tolerability, particularly in populations where cognitive or functional preservation is critical, such as working adults or elderly patients on polypharmacy regimens. Clinicians should recognize that functional cannabis products operate on different pharmacodynamic principles than traditional cannabis, potentially offering a distinct risk-benefit profile worthy of consideration in individualized treatment planning. As these products gain market prominence, evidence-based dosing, consistency in labeling, and standardization across manufacturers will become essential for safe clinical integration. For practitioners, understanding the distinction between functional and intoxicating cannabis formulations enables more informed patient counseling and selection of cannabinoid profiles aligned with specific therapeutic goals and lifestyle factors. Dr. Caplan’s Take “What we’re seeing with these [non-intoxicating cannabinoids](https://cedclinic.com/cbg-clinical-trial-anxiety-stress-relief/) is a genuine expansion of clinical utility, but we need to be honest that the marketing narrative has gotten ahead of the science in many cases, and patients deserve practitioners who can distinguish between preliminary promise and established efficacy.” Clinical Perspective The emerging market for “functional cannabis” products, particularly those emphasizing CBD and lower THC ratios, reflects growing consumer interest in [cannabinoid therapeutics](https://cedclinic.com/medcan3-trial-cancer-symptoms/) outside traditional recreational use. While CBD’s favorable safety profile and lack of intoxication may appeal to patients seeking symptom relief without [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/), clinicians should recognize that evidence for efficacy remains mixed and inconsistent across purported indications, with most robust data limited to specific seizure disorders and certain anxiety conditions. The marketing of these products as “functional” or wellness-focused can blur the line between therapeutic claims and supplement positioning, creating regulatory ambiguity and potential liability if patients forgo proven treatments based on unsubstantiated promises. Additionally, product quality and cannabinoid quantification remain problematic in many markets, and the long-term safety profile of chronic CBD exposure remains incompletely characterized. When patients ask about functional cannabis products, clinicians should engage in shared decision- 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20Rise%20of%20Functional%20Cannabis%3A%20Beyond%20Getting%20High%20%7C%20MEXC%20News%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55941)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55941)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20Rise%20of%20Functional%20Cannabis%3A%20Beyond%20Getting%20High%20%7C%20MEXC%20News%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55941)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Clinical Trial: Marijuana Oil With THC and CBD May Reduce Pain and Improve Sleep in …](https://cedclinic.com/clinical-trial-marijuana-oil-with-thc-and-cbd-may-reduce-pain-and-improve-sleep-in/) - [Cannabis can blur, reshape your memory, Washington State University study finds](https://cedclinic.com/cannabis-induced-memory-dysfunction-clinical-insights/) 📰 Source: [https://www.mexc.com/news/1104526](https://www.mexc.com/news/1104526) Further Reading Cannabis Policy Wire[Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) CED Clinic Blog[Fear of recurrence, secondary cancers, and health problems in long-term survivors of childhood cancer: Findings from a Canadian cohort.](https://cedclinic.com/fear-of-recurrence-secondary-cancers-and-health-problems-in-long-term-survi/) CED Clinic Blog[Associations of cannabis use, other substances, and lifestyle choices on anxiety in medical cannabis patients across 45 days.](https://cedclinic.com/associations-of-cannabis-use-other-substances-and-lifestyle-choices-on-anxi/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).